The pectins induced significant cytotoxicity and reduced Gal-3 expression <i>in vitro</i>, suggesting that biomaterials with a similar Gal:Ara ratio may be employed as adjuvants in GBM therapy. The gene discussed is LGALS3; the disease is glioblastoma.